Structure-based drug design is the design and ... This approach significantly suppresses both anti-PD-1-responsive and -resistant tumor growth, particularly in brain tumors.

Request permissions for this article.

1998). This terminal structure [Galβ(1,3)(Fucα(1,4))GlcNAc], known as Lewis A (Le a) epitope, appears predominantly on extracellular membrane-bound or soluble glycoproteins, suggesting that it plays a ...